Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
82.02
+0.29 (0.35%)
After Hours: 82.02 0.00 (0.00%)
Sep 20, 6:20PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 81.39 - 82.42
52 week 64.18 - 86.72
Open 82.06
Vol / Avg. 0.00/3.37M
Mkt cap 90.30B
P/E 35.55
Div/yield 0.52/2.54
EPS 2.31
Shares 1.10B
Beta 0.34
Inst. own 78%
Dec 13, 2017
Eli Lilly and Co 2018 Financial Guidance Call - 10:00AM EST - Add to calendar
Oct 24, 2017
Q3 2017 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Oct 24, 2017
Q3 2017 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Sep 12, 2017
Eli Lilly and Co at Morgan Stanley Healthcare Conference - Webcast
Jul 25, 2017
Q2 2017 Eli Lilly and Co Earnings Release
Jul 25, 2017
Q2 2017 Eli Lilly and Co Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 17.31% 12.90%
Operating margin 21.71% 16.30%
EBITD margin - 25.29%
Return on average assets 10.29% 7.36%
Return on average equity 28.74% 19.16%
Employees 41,975 -
CDP Score - A-

Address

Lilly Corporate Ctr, Drop Code 1112
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Officers and directors

David A. Ricks Chairman of the Board, President, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 52
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 63
Bio & Compensation  - Reuters
Melissa Stapleton Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 48
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 54
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 51
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Age: 50
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 52
Bio & Compensation  - Reuters
Barton R. Peterson Senior Vice President - Corporate Affairs and Communications
Age: 58
Bio & Compensation  - Reuters
Leigh Ann Pusey Senior Vice President - Corporate Affairs and Communications
Bio & Compensation  - Reuters